Evidence map›Paper›PMID 39304183›Full record

ArticleJournal of the American Society for Mass Spectrometry2024

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS).

Carmen Llorens-Cebrià, Norberto Núñez-Seral, Yolanda Villena-Ortiz, Irene Martínez-Díaz, Maria José Soler, Roser Ferrer-Costa, Conxita Jacobs-Cachá, Joan López-Hellín

Abstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carmen Llorens-CebriàNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Norberto Núñez-SeralHigh Technology Unit. Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Yolanda Villena-OrtizClinical Biochemistry Department. Vall d'Hebron University Hospital. Clinical Biochemistry, drug delivery and therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Irene Martínez-DíazNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Maria José SolerNephrology and Transplantation Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Roser Ferrer-CostaClinical Biochemistry Department. Vall d'Hebron University Hospital. Clinical Biochemistry, drug delivery and therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0002-8925-3172
Conxita Jacobs-CacháClinical Biochemistry Department. Vall d'Hebron University Hospital. Clinical Biochemistry, drug delivery and therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0003-2518-7847
Joan López-HellínClinical Biochemistry Department. Vall d'Hebron University Hospital. Clinical Biochemistry, drug delivery and therapy Research Group, Vall d'Hebrón Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist.

Indexed as

Apolipoprotein A-IMass SpectrometryTrypsinAmino Acid SequenceChromatography, LiquidHumansMolecular Sequence DataPeptide FragmentsApolipoprotein A-IPeptide FragmentsTrypsin

Identifiers

PMID39304183
PMCPMC11450815

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.